These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31627768)

  • 21. Predictors of recurrence of multidrug-resistant and extensively drug-resistant tuberculosis.
    Blöndal K; Viiklepp P; Guðmundsson LJ; Altraja A
    Int J Tuberc Lung Dis; 2012 Sep; 16(9):1228-33. PubMed ID: 22748131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects.
    Yew WW
    Kekkaku; 2011 Jan; 86(1):9-16. PubMed ID: 21401001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.
    Borisov SE; Dheda K; Enwerem M; Romero Leyet R; D'Ambrosio L; Centis R; Sotgiu G; Tiberi S; Alffenaar JW; Maryandyshev A; Belilovski E; Ganatra S; Skrahina A; Akkerman O; Aleksa A; Amale R; Artsukevich J; Bruchfeld J; Caminero JA; Carpena Martinez I; Codecasa L; Dalcolmo M; Denholm J; Douglas P; Duarte R; Esmail A; Fadul M; Filippov A; Davies Forsman L; Gaga M; Garcia-Fuertes JA; García-García JM; Gualano G; Jonsson J; Kunst H; Lau JS; Lazaro Mastrapa B; Teran Troya JL; Manga S; Manika K; González Montaner P; Mullerpattan J; Oelofse S; Ortelli M; Palmero DJ; Palmieri F; Papalia A; Papavasileiou A; Payen MC; Pontali E; Robalo Cordeiro C; Saderi L; Sadutshang TD; Sanukevich T; Solodovnikova V; Spanevello A; Topgyal S; Toscanini F; Tramontana AR; Udwadia ZF; Viggiani P; White V; Zumla A; Migliori GB
    Eur Respir J; 2017 May; 49(5):. PubMed ID: 28529205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
    Tiberi S; Payen MC; Sotgiu G; D'Ambrosio L; Alarcon Guizado V; Alffenaar JW; Abdo Arbex M; Caminero JA; Centis R; De Lorenzo S; Gaga M; Gualano G; Roby Arias AJ; Scardigli A; Skrahina A; Solovic I; Sulis G; Tadolini M; Akkerman OW; Alarcon Arrascue E; Aleska A; Avchinko V; Bonini EH; Chong Marín FA; Collahuazo López L; de Vries G; Dore S; Kunst H; Matteelli A; Moschos C; Palmieri F; Papavasileiou A; Spanevello A; Vargas Vasquez D; Viggiani P; White V; Zumla A; Migliori GB
    Eur Respir J; 2016 Apr; 47(4):1235-43. PubMed ID: 26965290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival of patients with multidrug-resistant TB in Eastern Europe: what makes a difference?
    Balabanova Y; Ignatyeva O; Fiebig L; Riekstina V; Danilovits M; Jaama K; Davidaviciene E; Radiulyte B; Popa CM; Nikolayevskyy V; Drobniewski F
    Thorax; 2016 Sep; 71(9):854-61. PubMed ID: 27012887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives.
    Pontali E; Raviglione MC; Migliori GB;
    Eur Respir Rev; 2019 Jun; 28(152):. PubMed ID: 31142549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres.
    Riccardi N; Alagna R; Saderi L; Ferrarese M; Castellotti P; Mazzola E; De Lorenzo S; Viggiani P; Udwadia Z; Besozzi G; Cirillo D; Sotgiu G; Codecasa L;
    BMC Infect Dis; 2019 Jun; 19(1):564. PubMed ID: 31253115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extensively drug-resistant tuberculosis in the United States, 1993-2007.
    Shah NS; Pratt R; Armstrong L; Robison V; Castro KG; Cegielski JP
    JAMA; 2008 Nov; 300(18):2153-60. PubMed ID: 19001626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A cross-sectional study about knowledge and attitudes toward multidrug-resistant and extensively drug-resistant tuberculosis in a high-burden drug-resistant country.
    Javed H; Tahir Z; Hashmi HJ; Jamil N
    Int J Mycobacteriol; 2016 Jun; 5(2):128-34. PubMed ID: 27242222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trends in drug-resistant tuberculosis in China: data from a clinical tuberculosis centre.
    Liao S; Cai C; Huo FM; Wu JN; Kong CC; Huang HR; Xu SF; Sun ZG
    Int J Tuberc Lung Dis; 2017 Sep; 21(9):990-995. PubMed ID: 28826447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost of multi drug resistance tuberculosis in Germany.
    Diel R; Nienhaus A; Lampenius N; Rüsch-Gerdes S; Richter E
    Respir Med; 2014 Nov; 108(11):1677-87. PubMed ID: 25443398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extensively drug-resistant tuberculosis in Myanmar: burden and mutations causing second-line drug resistance.
    Ei PW; Aung WW; Nyunt WW; Swe TL; Htwe MM; Win SM; Aung ST; Chang CL; Lee HY; Lee JS
    Int J Tuberc Lung Dis; 2018 Jan; 22(1):47-53. PubMed ID: 29297425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
    Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran.
    Velayati AA; Masjedi MR; Farnia P; Tabarsi P; Ghanavi J; ZiaZarifi AH; Hoffner SE
    Chest; 2009 Aug; 136(2):420-425. PubMed ID: 19349380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.
    Pontali E; Visca D; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
    Curr Opin Pulm Med; 2018 May; 24(3):244-252. PubMed ID: 29470252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extensively drug-resistant tuberculosis in california, 1993-2006.
    Banerjee R; Allen J; Westenhouse J; Oh P; Elms W; Desmond E; Nitta A; Royce S; Flood J
    Clin Infect Dis; 2008 Aug; 47(4):450-7. PubMed ID: 18616396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.
    Centers for Disease Control and Prevention (CDC)
    MMWR Recomm Rep; 2009 Feb; 58(RR-3):1-43. PubMed ID: 19214162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Challenging MDR-TB clinical problems - The case for a new Global TB Consilium supporting the compassionate use of new anti-TB drugs.
    Tiberi S; Pontali E; Tadolini M; D'Ambrosio L; Migliori GB
    Int J Infect Dis; 2019 Mar; 80S():S68-S72. PubMed ID: 30690212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of isoniazid resistance-conferring mutations associated with multidrug-resistant tuberculosis in Free State Province, South Africa.
    Pitso L; Potgieter S; Van der Spoel van Dijk A
    S Afr Med J; 2019 Aug; 109(9):659-664. PubMed ID: 31635590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Getting personal perspectives on individualized treatment duration in multidrug-resistant and extensively drug-resistant tuberculosis.
    Heyckendorf J; Olaru ID; Ruhwald M; Lange C
    Am J Respir Crit Care Med; 2014 Aug; 190(4):374-83. PubMed ID: 24941306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.